Biopharma firm to buy Botox manufacturer for $63B

2017 11 13 19 30 9377 Botox 400

Biopharmaceutical company AbbVie has announced an agreement to acquire Allergan, a pharmaceutical company and a manufacturer of Botox.

AbbVie will acquire Allergan for about $63 billion in cash and stock, according to the companies. The purchase is expected to close in early 2020.

Botox is a neurotoxin that temporarily paralyzes muscles and is used to treat movement disorders and migraines, as well for dental aesthetics and dental therapeutics such as treating temporomandibular joint disorders (TMDs) and pain.

Page 1 of 182
Next Page